XENERGY INC (XE)
NASDAQIndustrialsIndustrial - MachinerySnapshot 2026-09-04
NASDAQIndustrialsIndustrial - MachinerySnapshot 2026-09-04
Research Workspace
Put XE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Industrial Machinery & Supplies & Components is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — reduce losses from -$0.47 EPS in FY 2026 toward breakeven: EPS -0.15 vs breakeven target.
View ThesisThis stock is volatile — it swings about 4% on a typical day and fell roughly 62% in its worst 12-month stretch.
View RiskXE's growth relies on advancing the Xe-100 small modular reactor project. Revenue surged 154% year over year, but the latest earnings miss raises concerns. XE trades at a low valuation compared to peers, suggesting the price reflects expected growth. The primary risk is the potential for continued earnings misses, with a 49% chance of missing next quarter. Peer multiples imply a price about 53% above where it trades. Our read is provisional.
Trailing returns as of 2026-09-04. XE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering XE (as of Sep 2026).
Based on 5 Wall Street analysts offering 12-month price targets for XE in the last 4 months.
Continue this research
Compare XE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| XE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Industrial Machinery & Supplies & Components — fair value, gap to price, and forward P/E.
Compare the value case
Put XE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance Xe-100 SMR development and regulatory approvals
AI demand supports Xe-100 development and regulatory approvals.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $17.71
The last 12 months of price, then the range of analyst 12-month targets from today’s $17.71.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.

Advances: Advance Xe-100 SMR development and regulatory approvals
Significant revenue growth supports Xe-100 SMR development.

Advances: Advance Xe-100 SMR development and regulatory approvals
Funding supports Xe-100 SMR development and regulatory approvals.

Advances: Advance Xe-100 SMR development and regulatory approvals
Additional funding enhances growth potential for nuclear project.

Advances: Expand commercial collaborations with utilities and customers
Significant revenue growth supports commercial collaborations objective.
